ProPhase Labs, Inc. Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31)
ProPhase Labs, Inc. (PRPH) reported Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) of 26.42% for the 12-month period ending 2015-12-31, per its 10-K filed 2017-02-24.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsExpectedVolatilityRate · last filed 2017-02-24
- ProPhase Labs, Inc. fair value assumptions, expected volatility rate (deprecated 2018-01-31) for fiscal 2015 was 26.42%, a 49.61% decline from fiscal 2014.
- ProPhase Labs, Inc. fair value assumptions, expected volatility rate (deprecated 2018-01-31) for fiscal 2014 was 52.43%.
- ProPhase Labs, Inc. fair value assumptions, expected volatility rate (deprecated 2018-01-31) for fiscal 2012 was 83.06%.
| Period end | Fair Value Assumptions, Expected Volatility Rate (Deprecated 2018-01-31) 12 month |
|---|---|
| 2015-12-31 | 26.42% 10-K · filed 2017-02-24 |
| 2014-12-31 | 52.43% 10-K · filed 2017-02-24 |
| 2012-12-31 | 83.06% 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |